Treadwell Therapeutics Announces A Presentation at the 2022

Treadwell Therapeutics Announces A Presentation at the 2022 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor

/PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced that...

Related Keywords

San Antonio , Texas , United States , Canada , Toronto , Ontario , Philippe Bedard , Princess Margaret Cancer Centre , University Of Toronto , Henryb Gonzalez Convention Center , San Antonio Breast Cancer Symposium , Convention Center , Associate Professor , Staff Medical Oncologist , Michael Tusche , Phasei Trial , Advanced Solid Tumors , Negative Breast Cancer Expansion , Treadwell Therapeutics , Pharmaceuticals , Health Care Amp Hospitals , Medical Pharmaceuticals , Clinical Trials Amp Medical Discoveries ,